职称：教授，博士
联系方式：南方医科大学药学院
Email: yulezy@smu.edu.cn; yule0423@gmail.com
主要招生方向：药理学、工业药学
工作经历：
2018/12-至今，南方医科大学，教授
2015/09-2017/04，加州大学San Diego分校药理系，访问学者
2011/12-2018/12，南方医科大学，药学院，副教授
2005/10-2011/11，南方医科大学，药学院，讲师
2003/07-2005/09，第一军医大学，中心实验室，助教
学习经历：
2005/10-2009/04，香港中文大学，医学院药理学系，博士
2000/08-2003/06，第一军医大学，药物研究所，硕士
1996/08-2000/06，中国药科大学化学制药专业，学士
承担课程：
《药理学》；《Pharmacology》；《药学英语》
社会工作：
Journal of Clinical Laboratory Analysis副主编
（https://onlinelibrary.wiley.com/page/journal/10982825/homepage/editorialboard.html）
科研课题：
1.BAP1突变肿瘤对BET抑制剂易感性的发现及其机制研究，国家自然科学基金面上项目，54万，2020.01-2023.12.
2.利用GNAQ突变与BET抑制剂合成致死作用靶向治疗葡萄膜黑色素瘤，广东省自然科学基金面上项目，10万，2022.01-2024.12
3.乙酰转移酶p300作为GNAQ突变葡萄膜黑色素瘤治疗新靶点的研究，广东省颐养健康慈善基金会，30万，2024.10-2026.10.
主要论著：
Zhou RH#, Wang HF#, Zhang GM#, Liu YW#, Liu XL, Li ZF, Shi GW, Yuan JL, Qu CM, Li Y, Chen L, Huang JN, Zhou HC, Dai LY, Bai CZ, Wang JG*, Yu L*, Li ZJ*, Li YL*. Targeted degradation of endogenous YAP by nanobody bioPROTAC inhibits tumor progression. Nature Communications, 2025, 16(1):9374.
Wang H, Zhou R, Cu C, Dai L, Hou R, Zheng L, Fu C, Shi G, Wang J, Li Y, Cen J, Xu X, Yu L*, Li Y*, Wang J*, Du Q*, Li Z*. GRP78 nanobody-directed immunotoxin activates innate immunity through STING pathway to synergize tumor immunotherapy. Advanced Science (Winh), 2025, 26: e2408086.
Zhou YL#, Liu XL#, Huang SS, Zhang GM, Jin XY, Chen L, Yu L*, Li YL*. YAP upregulation contributes to acquired resistance to BET inhibitors in uveal melanoma. Pigment Cell Melanoma Research, 2025, 38(4):e70036.
Liu X, Zhou R, Pan J, Li Z*, Yu L*, Li Y*. Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations. Pigment Cell Melanoma Research, 2024, 37(3):411-425.
Ding Y#, Zhou R#, Shi G#, Jiang Y#, Li Z, Xu X, Ma J, Huang J, Fu C, Zhou H, Wang H, Li J, Dong Z, Yu Q, Jiang K, An Y, Liu Y, Li Y, Yu L*, Li Z*, Zhang X*, Wang J*. Cadherin 17 nanobody-mediated near-infrared-II fluorescence imaging-guided surgery and immunotoxin delivery for colrectal cancer. Biomaterial Research, 2024, 28:0041.
Wang HF#, Zhou RH#, Xu FS#, Yang KJ, Zheng LH, Zhao P, Shi GW, Dai LY, Xu CC, Yu L*, Li ZJ*, Wang JH*, Wang JG*. Beyond canonical PROTAC: biological targeted protein degradation (bioTPD). Biomater Res, 2023, 27(1):72.
Zhang GM#, Huang SS#, Ye LX, Liu XL, Shi WH, Ren ZL, Zhou RH, Zhang JJ, Pan JX, Liu SW, Yu L*, Li YL*. Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors. Pharmacol Res, 2022, 184:106464.
Liu XL#, Zhang GM#, Huang SS, Shi WH, Ye LX, Ren ZL, Zhang JJ, Liu SW, Yu L*, Li YL*. PETN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma. Acta Pharmacol Sin, 2022, 43(9):2397-2409.
Xu YY#, Ren ZL#, Liu XL, Zhang GM, Huang SS, Shi WH, Ye LX, Luo X, Liu SW, Li YL*, Yu L*. BAP1 loss augments sensitivity to BET inhibitors in cancer cells. Acta Pharmacol Sin, 2022, 43(7):1803-1815.
Yu L*, Zhou D, Zhang G, Ren Z, Luo X, Liu P, Plouffe SW, Meng Z, Moroishi T, Li Y, Zhang Y, Brown JH, Liu S*, Guang KL*. Co-occurrence of BAP1 and SF3B1 mutations in uveal melanoma induces cellular senescence. Mol Oncol, 2022, 16(3):607-629
Luo X#, Xu Y#, Li Y#, Zhang G,Huang S,Liu X,Ren Z,Liu S,Yu L*. BAP1deletion abrogates growth and metastasis of murine cutaneous melanoma. Melanoma Res, 2021 31(2):119-129.
